Scribe Therapeutics brings specificity challenge into focus for CRISPR cardiometabolic drugs
CRISPR can lower cholesterol. The harder test is whether Scribe can make durability, precision, and scalability work in common disease.
How Tenaya Therapeutics, Inc. is positioning TN-401 against the limitations of current ARVC care
Could TN-401 change ARVC treatment strategy? Explore what Tenaya Therapeutics, Inc.’s RIDGE-1 data means for cardiac gene therapy.